Intersect ENT Inc (NASDAQ:XENT) CFO Jeryl L. Hilleman sold 12,833 shares of Intersect ENT stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $29.96, for a total transaction of $384,476.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Intersect ENT Inc (NASDAQ:XENT) traded up 2.60% on Thursday, reaching $31.60. 233,999 shares of the company’s stock traded hands. The company’s 50-day moving average price is $30.43 and its 200 day moving average price is $25.54. The firm’s market cap is $922.37 million. Intersect ENT Inc has a one year low of $7.65 and a one year high of $33.25.

Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.11. The firm had revenue of $24.00 million for the quarter, compared to analysts’ expectations of $22.62 million. Intersect ENT had a negative net margin of 9.46% and a negative return on equity of 8.15%. The business’s quarterly revenue was up 24.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.21) EPS. On average, equities analysts forecast that Intersect ENT Inc will post ($0.61) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Insider Selling: Intersect ENT Inc (XENT) CFO Sells 12,833 Shares of Stock” was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/insider-selling-intersect-ent-inc-xent-cfo-sells-12833-shares-of-stock/1611112.html.

A number of research firms have recently weighed in on XENT. Zacks Investment Research upgraded shares of Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a research report on Thursday. Canaccord Genuity lifted their price target on shares of Intersect ENT from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Wednesday, September 13th. Bank of America Corporation lifted their price target on shares of Intersect ENT from $33.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, September 11th. Piper Jaffray Companies reiterated a “buy” rating and issued a $35.00 price target on shares of Intersect ENT in a research report on Tuesday, August 22nd. Finally, TheStreet upgraded shares of Intersect ENT from a “d” rating to a “c-” rating in a research report on Tuesday, August 1st. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $27.70.

A number of large investors have recently modified their holdings of XENT. ClariVest Asset Management LLC purchased a new position in shares of Intersect ENT in the first quarter valued at about $148,000. Legal & General Group Plc boosted its stake in shares of Intersect ENT by 3.8% during the 2nd quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after purchasing an additional 255 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of Intersect ENT by 109.1% during the 1st quarter. Cornerstone Capital Management Holdings LLC. now owns 11,500 shares of the medical equipment provider’s stock valued at $196,000 after purchasing an additional 6,000 shares in the last quarter. Moors & Cabot Inc. bought a new stake in shares of Intersect ENT during the 2nd quarter valued at about $205,000. Finally, Prudential Financial Inc. bought a new stake in shares of Intersect ENT during the 2nd quarter valued at about $229,000. Institutional investors own 83.12% of the company’s stock.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.